International Law Office
Trade Negotiators Seek Comment on Elimination of Pharmaceutical Import Duties
April 23, 2010
Over 9,000 pharmaceutical and chemical intermediates enjoy duty free treatment under the customs regime of the United States and other countries that participate in the World Trade Organization Pharmaceutical Agreement. The Office of the U.S. Trade Representative is seeking public comment on the possible expansion of the list of products subject to this reciprocal duty free treatment (comments were due by April 9, 2010).
This Sidley Update was republished by ILO in its Trade & Customs Newsletter.
Capabilities
Suggested News & Insights
Sidley Represents Orion Resource Partners in Combination of Sweetwater Royalties With Uranium RoyaltyApril 16, 2026Sidley Represents AIP in Its US$1.272 Billion Acquisition of Avanos MedicalApril 14, 2026Sidley Represents Telix Pharmaceutical in US$2.1 Billion Partnering Agreement With RegeneronApril 13, 2026Industrial Accelerator Act: A New Framework for EU (Sustainable) Industrial GrowthApril 9, 2026Five Key Takeaways from 2025 U.S. Sanctions EnforcementApril 7, 2026Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from TakedaApril 3, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory